help button home button Biophys. J.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dulhunty, A. F.
Right arrow Articles by Curtis, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dulhunty, A. F.
Right arrow Articles by Curtis, S.

Biophys J, July 1999, p. 189-203, Vol. 77, No. 1

Activation and Inhibition of Skeletal RyR Channels by a Part of the Skeletal DHPR II-III Loop: Effects of DHPR Ser687 and FKBP12

Angela F. Dulhunty, Derek R. Laver, Esther M. Gallant, Marco G. Casarotto, Suzy M. Pace, and Suzanne Curtis

Muscle Research Group, John Curtin School of Medical Research, Canberra, ACT 2601, Australia

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES

Peptides, corresponding to sequences in the N-terminal region of the skeletal muscle dihydropyridine receptor (DHPR) II-III loop, have been tested on sarcoplasmic reticulum (SR) Ca2+ release and ryanodine receptor (RyR) activity. The peptides were: A1, Thr671-Leu690; A2, Thr671-Leu690 with Ser687 Ala substitution; NB, Gly689-Lys708 and A1S, scrambled A1 sequence. The relative rates of peptide-induced Ca2+ release from normal (FKBP12+) SR were A2 > A1 > A1S > NB. Removal of FKBP12 reduced the rate of A1-induced Ca2+ release by ~30%. A1 and A2 (but not NB or A1S), in the cytoplasmic (cis) solution, either activated or inhibited single FKBP12+ RyRs. Maximum activation was seen at -40 mV, with 10 µM A1 or 50 nM A2. The greatest A1-induced increase in mean current (sixfold) was seen with 100 nM cis Ca2+. Inhibition by A1 was greatest at +40 mV (or when permeant ions flowed from cytoplasm to SR lumen) with 100 µM cis Ca2+, where channel activity was almost fully inhibited. A1 did not activate FKBP12-stripped RyRs, although peptide-induced inhibition remained. The results show that peptide A activation of RyRs does not require DHPR Ser687, but required FKBP12 binding to RyRs. Peptide A must interact with different sites to activate or inhibit RyRs, because current direction-, voltage-, cis [Ca2+]-, and FKBP12-dependence of activation and inhibition differ.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES

The ryanodine receptor (RyR) calcium channel mediates Ca2+ release from internal stores in many cell types and is an essential component of excitation-contraction coupling (ECC) in striated muscle. In skeletal muscle, the L-type Ca2+ channel (dihydropyridine receptor, DHPR) is the voltage sensor for ECC, i.e., it senses T-tubule depolarization and transmits a signal to the RyR, via a protein-protein interaction which requires the loop between the second and third repeats of the skeletal DHPR alpha 1 subunit (II-III loop; Tanabe et al., 1990). The II-III loop of the DHPR binds to a 37-amino acid sequence, Arg1076-Asp1112, in the skeletal muscle RyR (Leong and Maclennan, 1998).

The skeletal DHPR II-III loop increases [3H]ryanodine binding to sarcoplasmic reticulum (SR) vesicles, and activates purified RyR channels in lipid bilayers (Lu et al., 1994, 1995). Because ryanodine binds preferentially to open RyR channels, the increase in [3H]ryanodine binding suggests that native RyRs in SR vesicles are activated by the II-III loop. The N-terminal part of the II-III loop (Glu666-Glu726) also activates RyR channels, but fails to do so when Ser687 is either phosphorylated or replaced by alanine (Lu et al., 1995). A short peptide Thr671-Leu690 (peptide A) activates Ca2+ release from SR, but peptides corresponding to other segments of the loop do not (El-Hayek et al., 1995; El-Hayek and Ikemoto, 1998). Since the actions of peptide A on single RyR channels had not been reported, we examined its effects on RyRs. We also studied possible interactions between the regulation of RyRs by peptide A and their regulation by the FK506-binding protein (FKBP12), a co-protein that coordinates RyR activity. FKBP12 is intrinsic to normal RyR function and may be involved in ECC (Ahern et al., 1994, 1997a; Brillantes et al., 1994; Mayrleitner et al., 1994; Lamb and Stephenson, 1996). Four FK506-binding proteins (FKBP12, Mr ~12,000) are tightly bound to each RyR monomer (Jayaraman et al., 1992; Timerman et al., 1993; Wagenknecht et al., 1996, 1997). The immunosuppressant drugs FK506 and rapamycin bind to FKBP12 and dissociate it from the RyR (Timerman et al., 1993, 1995). RyRs "stripped" of their FKBP12 co-proteins display increased channel activity at low cytoplasmic Ca2+ concentrations, with a loss of coordinated channel opening to the maximum conductance (Ahern et al., 1997a).

In this study, the ability of peptide A1 (Thr671-Leu690) and peptide A2 (with Ser687 replaced by Ala687) to release Ca2+ from native FKBP12+ terminal cisternae (TC) vesicles and from FKBP12-stripped vesicles was examined, as well as the actions of the peptides on single native RyR channels incorporated into lipid bilayers. The results showed that peptide A1 released Ca2+ from FKBP12+ and FKBP12-stripped TC vesicles, although release from the RyRs lacking FKBP12 was markedly reduced. Ca2+ release by peptide A2 was greater than that by peptide A1. The peptides had a dual action on RyR channel activity. Activation at -40 mV was greatest with 100 nM cis Ca2+, while inhibition at +40 mV was strongest with 100 µM cis Ca2+. Channel activation by the peptide was markedly reduced in FKBP12-stripped RyRs. The inhibition of channel activity was strongest when current flowed from the cytoplasmic to the luminal side of the RyR and preferentially blocked channel opening to maximum conductance levels. The results show that these small DHPR II-III loop peptides can both activate and inhibit single RyR channels and are likely to act on at least two separate sites on the RyR channel protein.

    METHODS
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES

Materials

Rapamycin was obtained from Calbiochem and as a gift from Wyeth-Ayerst (Princeton, NJ). Other chemicals and biochemicals were from Sigma-Aldrich (Castle Hill, Australia). The DHPR II-III loop peptides were synthesized using an Applied Biosystems 430A Peptide Synthesiser with purification to 98 to 100% using HPLC and mass spectroscopy. Peptide conformation was determined using NMR. Stock peptide solutions (~2 mM) were prepared in H20 and frozen in 20-µl aliquots. Precise stock solution concentrations were determined (Auspep Pty Ltd) using acid hydrolysis followed by a standardized PTC (phenylthiocarbamyl) protocol and analyzed by reverse phase HPLC. The following peptides were used in this study.

Peptide A1

671Thr Ser Ala Gln Lys Ala Lys Ala Glu Glu Arg Lys Arg Arg Lys Met Ser Arg Gly Leu690.

Peptide A2

671Thr Ser Ala Gln Lys Ala Lys Ala Glu Glu Arg Lys Arg Arg Lys Met Ala Arg Gly Leu690.

Peptide NB

689Gly Leu Pro Asp Lys Thr Glu Glu Glu Lys Ser Val Met Ala Lys Lys Leu Glu Gln Lys708.

Peptide A1S

Thr Arg Lys Ser Arg Leu Ala Arg Gly Gln Lys Ala Lys Ala Lys Ser Glu Met Arg Glu.

Vesicle preparation

SR vesicles were isolated from the back and leg muscles of New Zealand White rabbits using methods described by Saito et al. (1984) with minor modifications (Ahern et al., 1994, 1997a). Native FKBP12+ TC vesicles were obtained from the 38%/45% sucrose interface after sucrose gradient centrifugation. FKBP12 was "stripped" from TC vesicles by incubating the vesicles with 20 µM rapamycin for 20 min at 37°C, followed by centrifugation at 540,000 × g (and then resuspension) to remove rapamycin and the FKBP12-rapamycin complex. The amount of FKBP12 remaining bound to the TC vesicles was assessed by immunostaining Western blots of the vesicles with anti-peptide antibodies raised against peptides corresponding to the N-terminal sequence of FKBP12. The incubation procedure with rapamycin removed all detectable FKBP12 from each of the 14 preparations used in the present experiments. "FKBP12+-incubated" vesicles, incubated for 20 min at 37°C in the absence of rapamycin, retained an amount of FKBP12 similar to that seen in native B4 vesicles. Details of the FKBP12 "stripping" procedure, production of anti-peptide antibodies, electrophoresis, and Western blotting are given in Ahern et al. (1997a).

Calcium release from TC vesicles

Extravesicular Ca2+ was monitored at 710 nm with the Ca2+ indicator, antipyrylazo III, using a Cary 3 spectrophotometer. Identical release experiments, performed at 790 nm, showed no changes in optical density (OD) that would alter the rate of Ca2+ uptake measured from recordings at 710 nm. A step increase in OD upon addition of ruthenium red was seen in recordings at both 710 nm and 790 nm, and was subtracted from the records shown in Figs. 1 and 2 (see Results). The temperature of the cuvette solution was thermostatically controlled at 25°C and the solution was stirred with a magnetic stirrer. Ca2+ release was measured as described by Timerman et al. (1993). TC vesicles (100 µg protein) were added to the cuvette, to a final volume of 2 ml, of a solution containing (in mM): 100, KH2PO4 (pH = 7); 4, MgCl2; 1, Na2ATP; 0.5, antipyrylazo III). Vesicles were partially loaded with Ca2+ by four sequential additions of CaCl2, each initially increasing the extravesicular [Ca2+] by ~7.5 µM (see Figs. 1 and 2). It was necessary to also suppress Ca2+,Mg2+-ATPase activity after loading (using thapsigargin, 200 nm; Sagara and Inesi, 1991), to allow extravesicular [Ca2+] to increase after activation of the RyR. Peptide or caffeine were the then added, followed by the RyR blocker ruthenium red (to a final concentration of 5 µM), to determine whether Ca2+ release through RyR channels was responsible for Ca2+ release from SR. The Ca2+ ionophore A23187 (3 µg/ml) was finally added to release the Ca2+ remaining in the TC vesicles. A calibration curve was established at the start of each experiment by measuring OD changes in response to four sequential additions of 12.5 µM CaCl2.

Lipid bilayers

Experiments were carried out at 20-25°C. The techniques are described in Ahern et al. (1994) and Laver et al. (1995). Bilayers were formed from phosphatidylethanolamine, phosphatidylserine, and phosphatidylcholine (5:3:2 w/w) (Avanti Polar Lipids, Alabaster, AL) across an aperture with a diameter of 200-250 µm in the wall of a 1.0-ml Delrin cup (Cadillac Plastics, Australia). In some experiments (e.g., Fig. 7) bilayers contained only phosphatidylethanolamine and phosphatidylcholine (8:2 w/w). In these experiments the negatively charged phosphatidylserine was left out to remove possible effects on channel activity of bilayer surface potential changes during changes in ionic composition.

TC vesicles (final concentration, 10 µg/ml) and drugs were added to the cis chamber. The bilayer potential was controlled, and single channel activity recorded, using an Axopatch 200A amplifier (Axon Instruments, Foster City, CA). For experimental purposes, the cis chamber was held at ground and the voltage of the trans chamber controlled. Bilayer potential is expressed in the conventional way as Vcis - Vtrans, (i.e., Vcytoplasm - Vlumen).

Bilayer solutions

Bilayers were formed and vesicles incorporated into the bilayer using a cis solution containing 250 mM CsCl (or 230 mM cesium methanesulfonate (MS) plus 20 mM CsCl), 1 mM CaCl2, and 10 mM N-tris[hyroxymethyl]methyl-2-aminoethanesulfonic acid (TES, pH 7.4 with CsOH) and a trans solution containing 50 mM CsCl (or 30 mM CsMS plus 20 mM CsCl), 1 mM CaCl2, and 10 mM TES (pH 7.4). To prevent incorporation of multiple channels into the bilayer, the cis solution was replaced by perfusion of the cis chamber as soon as channel activity was observed. The cis perfusion solution was identical to the initial cis solution, except that the [Ca2+] was varied (10-7 M or 10-4 M) as required. Ca2+ was buffered to 10-7 M or 10-5 M using 1 mM BAPTA; 200 mM CsMS was added to the trans chamber after channel incorporation to give symmetrical solutions.

In experiments examining RyR channel activity over a range of peptide concentrations and at +40 mV and -40 mV, bilayer potential was changed every 30 s over a 2-min period after each addition of drugs or peptides to the cis chamber. Control activity was recorded for 2 min after addition of 200 mM CsMS to the trans chamber. Activity was then recorded for 2 min after cis additions of 2 mM Na2ATP, 4 mM MgCl2, or 2 mM MgCl2 and then after each aliquot of peptide (three to eight different peptide concentrations were examined in each channel). Peptides were perfused out of the cis chamber, and the channels were reexposed to Na2ATP plus MgCl2 and then finally to ruthenium red (10-80 µM). In some experiments 5 mM Ca2+ and 250 mM or 500 mM mannitol were added to the cis solution to aid vesicle incorporation.

Recording and analysis of single channel activity

Currents were filtered at 1 kHz (10-pole low-pass Bessel, -3 dB) and digitized at 5 kHz. Analysis of single channel records (using Channel 2, developed by P. W. Gage and M. Smith) yielded channel open probability (Po), frequency of events (Fo), open times, closed times, and mean open or closed times (To or Tc) as well as mean current (I'). The event discriminator was set above the baseline noise at ~20% of the maximum current, rather than the usual 50%, so that openings to both subconductance and maximum conductance levels were included in the analysis. Channel activity was analyzed over two 30-s periods of continuous activity at +40 mV and two 30-s periods of continuous activity at -40 mV.

Values for the peptide concentration required for 50% activation (AC50) and for 50% inhibition (IC50) of mean current (I') were obtained from graphs of I' as a function of peptide concentration, [P] (Figs. 5 and 6). Some data were fitted with the equation
I′=(I′<SUB><UP>c</UP></SUB>+I′<SUB><UP>max</UP></SUB>/(1+<UP>AC</UP><SUB>50</SUB>/[<UP>P</UP>]))/(1+([<UP>P</UP>]/<UP>IC</UP><SUB>50</SUB>)<SUP><UP>H</UP></SUP>)
where I'c is the control I', I'max is the maximum current during activation, and H is the Hill coefficient.

Statistics

Average data are given as mean ± SEM. The significance of the difference between control and test values was tested 1) using a Student's t-test, either one- or two-sided and either for independent or paired data, as appropriate; or 2) using the nonparametric "sign" test (Minium et al., 1993). Differences were considered to be significant when p <=  0.05.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES

Peptide A1 releases Ca2+ from terminal cisternae

The ability of peptide A1 to release Ca2+ from native FKBP12+ TC vesicles was examined. As previously reported (El-Hayek et al., 1995; El-Hayek and Ikemoto, 1998), A1 released Ca2+ from TC. In the present experiments, extravesicular [Ca2+] increased when 200 nM thapsigargin was added to the cuvette after loading the SR with Ca2+ (Fig. 1, A and D).



View larger version (20K):
[in this window]
[in a new window]
 
FIGURE 1   Peptides A1S, A1, and A2 release Ca2+ from partially loaded native FKBP12+ TC vesicles. (A)-(D) Records of OD changes at 710 nm, with changes in extravesicular [Ca2+], measured using antipyrylazoIII (500 µM) as the Ca2+ indicator. In each record, extravesicular [Ca2+] increased when TC vesicles were added to the cuvette (**) and then declined as Ca2+ was sequestered by the TC vesicles. The next four positive deflections (*) indicate addition of each aliquot of CaCl2 (7.5 µM, final concentration). The first arrow (t) indicates addition of 200 nM thapsigargin to block the SR Ca2+ ATPase. The second arrow (P) indicates addition of (A) 19 µM NB; (B) 36 µM A1S; (C) 36 µM A1; (D) 29 µM A2. Ruthenium red (10 µM) was added at the third arrow (r), before the ionophore A23187 (last arrow, i, 3 µg/ml). The vertical calibration is in µM Ca2+ (addition of 10 µM extravesicular Ca2+, increased OD by 0.2 units). (E) Maximum rate of Ca2+ release (nM/mg of TC vesicles/min) induced by peptides A1 (n = 8, filled circles) or A1S (n = 6; filled squares). (F) Maximum rate of Ca2+ release (nM/mg/min) induced by peptide A2 (n = 11; filled circles) or NB (n = 3; filled squares) as a function of peptide concentration. The rates shown are the maximum rate of release with peptide minus the preceding rate with thapsigargin. Data points are averages ± SE, using TC vesicles from three different SR preparations.

The rate of Ca2+ release with thapsigargan, just before adding the peptide, was ~55 nM/mg/min. Addition of peptide NB did not alter the rate of Ca2+ release, A1S induced a small increase in Ca2+ release, and A1 caused a larger increase (Fig. 1, A-C). Ruthenium red (10 µM) stopped Ca2+ release, if added while extravesicular [Ca2+] was increasing (Fig. 1, A and D), suggesting that the Ca2+ release after addition of thapsigargin (Fig. 1 D), and activated by peptides A1 and A1S (Fig. 1 A), was through RyR channels. The rate of Ca2+ release induced by peptide A1 (maximum rate after A1 addition minus the rate in the presence of thapsigargin) of ±8 nmol/mg/min with 36 µM A1 (n = 8) was significantly greater (p = 0.007) than the 56 ± 10 nmol/mg/min with 36 µM A1S (n = 6, Fig. 1 E).

Activation by A1S suggests that peptides containing positively charged residues in any sequence can induce Ca2+ release from SR, via activation of RyRs. This observation is consistent with the ability of polylysine to release Ca2+ from SR (El-Hayek and Ikemoto, 1998).

Ser687 is not essential for peptide activation of Ca2+ release from SR

Surprisingly, and in contrast to results obtained with the full-length II-III loop peptide (Lu et al., 1995), the Ser687 Ala substitution increased the ability of peptide A to activate Ca2+ release from native FKBP12+ TC vesicles. Ca2+ release induced by A2 was significantly (p < 0.05) greater than that induced by peptide A1 and increased to 191 ± 38 nM/mg/min (n = 11) with 29 µM peptide (filled circles, Fig. 1 F). As with A1, the A2-induced Ca2+ release from SR was substantially reduced by 10 µM ruthenium red (Fig. 1 D) and was thus through RyR channels.

Ca2+ release with A1 is less after FKBP12 removal

The experiments were repeated with FKBP12+-incubated and with FKBP12-stripped TC vesicles. FKBP12-stripped vesicles required longer loading times than native or FKBP+-incubated vesicles (12 of 12 preparations) as expected from the greater RyR activity after FKBP12 removal (Ahern et al., 1994, 1997a; Table 4). Since the rate of depletion of extravesicular Ca2+ is equal to the rate of Ca2+ uptake minus the rate of Ca2+ release, load time increases if release increases. The time allowed for loading was increased to ~4 min between each addition of CaCl2 for both FKBP12+-incubated and FKBP12-stripped TC (prepared in parallel from the same native TC preparation). Data were obtained from vesicles from at least three different preparations. The amount of Ca2+ loaded, determined from the difference between the OD after the last load step and the OD 4 min after A23187 addition, was 94.0 ± 0.3% (n = 25) of the Ca2+ added to the extravesicular solution for FKBP12+-incubated and 93.1 ± 0.7% (n = 22) in FKBP12-stripped vesicles. Peptide A1 (36 µM) was significantly less effective at releasing Ca2+ from FKBP12-stripped TC (Fig. 2 B) than from the FKBP12+-incubated TC (Fig. 2 A) at all peptide concentrations (Fig. 2 C).



View larger version (26K):
[in this window]
[in a new window]
 
FIGURE 2   Peptide A1-induced Ca2+ release from partially loaded FKBP12-stripped TC vesicles was less than that from FKBP12+-incubated TC. (A) and (B) show records of OD changes at 710 nm, with changes in extravesicular [Ca2+], using antipyrylazoIII (500 µM) as a Ca2+ indicator. The Ca2+ loading procedure is the same as in Fig. 1. The first arrow (t) in each record indicates the addition of 200 nM thapsigargin. The second arrow (P) indicates addition of 36 µM of peptide A1 to (A) FKBP12+-incubated vesicles and (B) FKBP12-stripped vesicles. Ruthenium red (third arrow, r, 10 µM) was added before the ionophore A23187 (last arrow, i, 3 µg/ml). The vertical calibration is in µM of Ca2+ (adding 10 µM extravesicular Ca2+ increased OD by 0.2 units). (C) Histograms of the initial rate of Ca2+ release (nM/mg/min of TC vesicle) in the presence of peptide A1 (6-36 µM), from FKBP12+-incubated (n = 6; double cross-hatched bars) or FKBP12-stripped (n = 6; cross-hatched bars). Rates are the maximum rate with peptide minus the preceding rate with thapsigargin. (C, inset) Rate of Ca2+ release after adding peptide NB minus the preceding rate with thapsigargin (n = 2). (D) Initial rate of release as fraction of the releasable Ca2+, rather than [Ca2+] per se (see text description). Data points are averages ±SEM using TC vesicles from three different SR preparations.

The reduced Ca2+ release from FKBP12-stripped vesicles might have been due to factors other than the absence of FKBP12. For example, the number of vesicles containing active RyR channels might have been reduced after FKBP12 removal. To test this possibility, the amount of Ca2+ that could be released through RyR channels ("releasable Ca2+") was measured by adding 5 mM caffeine after thapsigargin, and expressing the increase in extravesicular [Ca2+] after 6 min as a fraction of the Ca2+ loaded. Releasable Ca2+ was 64 ± 10 5% in FKBP12+-incubated TC and 54 ± 4% in the FKBP12-stripped TC (each number is the average from two different preparations). The effect of FKBP12 removal on the ability of the TC to release Ca2+ in general was examined by looking at the release in response to 0.5 mM caffeine (a submaximal concentration). The maximum rate of Ca2+ release in response to caffeine was expressed as a fraction of the releasable Ca2+. The rates were 13 ± 3%/min (n = 2) for FKBP12+-incubated TC and 12 ± 1%/min (n = 2) for FKBP12-stripped TC. Thus the rates of release in response to caffeine were not influenced by FKBP12 removal.

Rates of A1-activated Ca2+ release were adjusted for differences in the amounts of releasable Ca2+ between FKBP12+-incubated and FKBP12-stripped TC (Fig. 2 D). The A1-activated Ca2+ release from the FKBP12-stripped RyRs remained significantly less than that from FKBP12+-incubated RyRs at all peptide concentrations. The smaller peptide-induced Ca2+ release from the FKBP12-stripped vesicles suggests that FKBP12 facilitates the activation of RyRs by the II-III loop peptides.

Addition of peptide NB to one pair of stripped and FKBP12+-incubated vesicle preparations did not evoke Ca2+ release (Fig. 2 C, inset); the apparent negative release is due to the fact that the release in the presence of thapsigargin became slower with time, so that subtraction of the latter part of the record from the initial part gave a negative rate.

Effects of peptide A1 on single RyR channels at different cytoplasmic [Ca2+]

Single RyR activity

Peptide A1 (6.5 nM to 32.5 µM) was added to the cis chamber, with 250/250 mM Cs+ (cis/trans), a [Ca2+] of 10-7M, 10-5M, or 10-4M (cis) and 10-3 M (trans), 2 mM cis Na2ATP, and 2 or 4 mM MgCl2, with bilayer potentials of -40 mV or +40 mV. A1 had excitatory and inhibitory effects on FKBP12+ native channels (Fig. 3).



View larger version (32K):
[in this window]
[in a new window]
 
FIGURE 3   Biphasic action of peptide A1 on single native FKBP12+ RyR channels. A1 at 6.5 µM or 32.5 µM increases the activity of recorded at -40 mV, and reversibly depresses activity at +40 mV, with 100 nM cis Ca2+ (A) or 100 µM cis Ca2+ (B). The first records in each panel were obtained under control conditions with 2 mM Na2ATP and 2 mM MgCl2 in the cis solution. The second and third sets of records show activity recorded after 10 s exposure to 6.5 µM or 32.5 µM A1, respectively. The final records were obtained ~4 min after removing peptide A1 from the cis chamber by perfusion with 5 vol cis solution plus 2 mM Na2ATP and 2 mM MgCl2. The continuous line in each record shows the closed channel current. The broken line shows the maximum open channel conductance.

RyR activity at -40 mV with 100 nM or 100 µM cis Ca2+ increased with 650 nM to 32.5 µM cis A1, with no change in the maximum open channel conductance (Fig. 3, A and B). Inhibition by 6.5 µM A1 (Fig. 3 A) was apparent at +40 mV, with fewer openings to the maximum conductance. There were substantially fewer openings at +40 mV during strong inhibition by 32.5 µM A1 and long openings (>1 s) to low submaximal conductance levels (Fig. 3 B). Channels recovered from the inhibitory effects of the peptide within 15 s after perfusion of the cis chamber with peptide-free cis solution. Channel activity remained higher than control, especially at -40 mV, for 3-7 min after washout. Activity declined at longer times after washout. Thus inhibition by peptide A1 is rapidly reversible, while activation is less reversible.

Effect of peptide A on the mean current through RyRs

A1 increased mean current through native FKBP12+ RyR channels at -40 mV in 17 of 17 bilayers (100 nM, 10 µM, and 100 µM cis Ca2+). The greatest average peptide A1-induced increase (~6-fold) in mean current (I') through RyRs occurred at -40 mV with 100 nM cis Ca2 (Fig. 4 A and Table 1).



View larger version (19K):
[in this window]
[in a new window]
 
FIGURE 4   Average effects of peptides A1 and A1S on the relative mean current flowing through native FKBP12+ RyRs at -40 mV and +40 mV. Relative mean current (I'p/I'c, where I'p is I' in the presence of peptide and I'c is I' under control conditions) is plotted against the logarithm of [peptide A] in nM. Symbols show average I'p/I'c and vertical bars show ±SEM where this is greater than the dimensions of the symbol. Results for A1 were obtained with (A) 100 nM cis Ca2+, 2 mM Na2ATP, 2 mM MgCl2 (n = 5); (B) 10 µM cis Ca2+, 2 mM Na2ATP, 2 mM MgCl2 (n = 6) or 4 mM MgCl2 (n = 3); (C) 100 µM cis Ca2+, 2 mM Na2ATP, 2 mM MgCl2 (n = 6). (D) Data for peptide A1S were obtained with 10 µM cis Ca2+, 2 mM Na2ATP, 2 mM MgCl2 (n = 8).


                              
View this table:
[in this window]
[in a new window]
 
TABLE 1   Average single channel parameters for native FKBP12+ RyRs at -40 or +40 mV exposed to peptide A1

Average normalized I' at -40 mV increased with A1 between 6.5 nM and 32.5 µM, reaching a maximum with ~6.5 µM peptide with half-maximum concentration between 65 and 650 nM at each cis [Ca2+]. I' at +40 mV also increased with [A1] at 100 nM and 10 µM cis Ca2+ (Fig. 4, A and B), but fell below control with A1 > 6.5 nM when cis [Ca2+] was 100 µM, where inhibition depressed I' below control values with a half-maximum [A1] of ~0.65 µM. It is likely that the decline in activation at higher peptide concentrations under the other conditions can be attributed to inhibition.

Activation by A1 overcame Mg2+ inhibition of RyRs. Data for 100 nM and 100 µM cis Ca2+ were obtained in the presence of 2 mM Na2ATP and 2 mM MgCl2, with a free Mg2+ of 0.6 mM, which inhibits RyRs by >50% (Laver et al., 1997a, b). Data for 10 µM cis Ca2+ were obtained with either 2 mM MgCl2 (n = 5) or 4 mM MgCl2 (n = 3, with a free Mg2+ of 2.1 mM, which inhibits skeletal RyRs by > 90%). Since 6.5 µM A1 caused similar 2.9 ± 0.9-fold increase with 2 mM MgCl2 or 3.2 ± 1.3-fold increase with 4 mM MgCl2, data for the two experiments were pooled for Fig. 4. A1-induced activation was seen in 13 other bilayers (data not shown) with 4 mM MgCl2, 2 mM Na2ATP, and 100 µM cis Ca2+.

Single channel characteristics of A1-activated RyRs

During the strongest activation by 6.5 µM A1 at -40 mV with 100 nM cis Ca2+, the open probability (Po) and open frequency (Fo) were significantly greater than normal, and mean closed time (Tc) was significantly reduced (Table 1). Po and Fo at -40 mV were similarly increased by 6.5 µM peptide when cis [Ca2+] was 100 µM. In contrast, with activating 10 µM cis Ca2+, mean open time (To) at -40 mV increased, while Fo was unaffected and indeed fell in two of the five channels. Although the changes in parameter values (I', Po, Fo, To, and Tc) for most individual channels at +40 mV were in the same direction as those at -40 mV, the average changes were significant only with 10 µM cis Ca2+ (Table 1). Since inhibition by A1 was strongest at +40 mV (Figs. 3 and 4 above), it presumably reduced the degree of activation at this potential.

Removal of peptide A1 enhances RyR activity

Activity often increased further after A1 was perfused out of the cis chamber. Average I' and Po were significantly greater than control (Table 1) after peptide removal, with all cis [Ca2+]s at -40 mV, while I', Po, Fo, and To were significantly greater than control, and Tc significantly less, at +40 mV with 100 nM or 10 µM cis Ca2+ (Table 1). As in the presence of A1, the greatest relative increase in I' after perfusion was at -40 mV with 100 nM cis Ca2+, where I' was double that before 32.5 µM A1 washout and ~13-fold greater than control. This result suggests that peptide A is rapidly removed from the blocking site after washout, but that it remains bound to the activation site. Furthermore, the increase in channel activity with A1 removal suggests that the degree of activation in the presence of A1 was suppressed by the simultaneous inhibitory action of the peptide. Data at +40 mV for the three cis [Ca2+]s were pooled to more clearly see the effects of activation or inhibition by peptide A1 and peptide washout (Table 2).


                              
View this table:
[in this window]
[in a new window]
 
TABLE 2   Average single channel parameters at +40 mV for pooled data obtained with 100 nM, 10 µM, and 100 µM cis Ca2+

There was a significant increase Fo with 6.5 µM A1 (reflecting activation), while Fo fell with 32.5 µM A1 (reflecting inhibition). Washout of 32.5 µM A1 resulted in significant increases in I', Po, Fo, and To, and a significant decrease in Tc (reflecting recovery from inhibition). This result remains consistent with the hypothesis that peptide A is rapidly removed from its blocking site, but not from its activation site, after washout.

Neither scrambled A1 (A1S) nor NB activates RyRs

The strong activation and inhibition of RyR channels induced by peptide A1 were not seen with A1S (Fig. 4 D). Similarly, I' was 0.79 ± 0.24 under control conditions and 0.92 ± 0.26 (n = 6) after addition of 9.3 µM of NB to the cis side of RyRs at +40 mV with 100 µM cis Ca2+. Po, To, Tc, and Fo were also unaffected by NB. Curiously, a small inhibition of channel activity was seen with A1S. I' (+40 mV) was less than control in six of seven bilayers with 62 nM and 620 nM cis A1S, and in seven of seven bilayers with 6.2 µM cis A1S. A fall in I' at -40 mV was also seen in four of seven bilayers after adding 6.2 µM A1S. The average data in Table 3 show that 6.2 µM A1S causes a significant reduction in To at -40 mV as well as significant reductions in Po, Fo, and To, or increase in Tc at +40 mV (Table 3).


                              
View this table:
[in this window]
[in a new window]
 
TABLE 3   Average single channel parameters for seven native FKBP12+ RyRs exposed to scrambled A1 (A1S) at +40 mV and -40 mV

It is likely that interactions between the positively charged residues in A1 and negative charges in the channel pore cause the strong channel block by A1 (see Discussion below). The clustered positive charges in the C-terminus of A1 presumably provide a high positive charge density that is effective in blocking the channel. The more diffuse charges in A1S may interact less effectively with the same negatively charged sites in the channel pore to give the weak channel block seen in Fig. 4 and Table 3.

Peptide A2 activates and inhibits native FKBP12+ channels

The Ser687 Ala substitution did not alter the overall ability of peptide A to activate or inhibit native FKBP12+ RyRs. However, A2 activated RyRs at considerably lower peptide concentrations (AC50 between 3.6 and 7.25 nM, Fig. 5), than those required for activation by A1 (AC50 of 65-650 nM, Fig. 4 above).



View larger version (20K):
[in this window]
[in a new window]
 
FIGURE 5   Peptide A2 activates native FKBP12+ RyRs at -40 mV and inhibits the RyRs at +40 mV. Relative mean current (I'p/I'c, where I'p is I' in the presence of peptide and I'c is I' under control conditions) is plotted against the logarithm of peptide A2 concentration (log[A2]) in nM. Symbols show average I'p/I'c and vertical bars show ±1 SEM where this is greater than the dimensions of the symbol. Results for A2 were obtained with (A) 10 µM cis Ca2+, with 2 mM Na2ATP and 2 mM MgCl2 (n = 6); (B) 100 µM cis Ca2+ with 2 mM Na2ATP and 4 mM MgCl2 (n = 12).

Although the affinity for A2 was higher than that for A1, the degree of activation induced by the two peptides was similar (~2.5-fold with 10 µM or 100 µM cis Ca2+). These results are consistent with the ability of peptide A2 to release Ca2+ from native FKBP12+ SR vesicles (above). A2 also overcame inhibition of RyRs by 0.6 mM free Mg2+ (with 2 mM MgCl2 in the 10 µM cis Ca2+ solution, n = 6), or 2.1 mM free Mg2+ (with 4 mM MgCl2 in the 100 µM cis Ca2+ solution, n = 12).

The affinity of the peptide for the inhibition site was also increased by the Ser687 Ala substitution. The IC50 at +40 mV was ~360 nM with 10 µM and 100 µM cis Ca2+. The cis [Ca2+]-dependence of peptide A2-inhibition differed from that with A1. A2 inhibited at +40 mV with 10 µM cis Ca2+ (dropping I' to ~28% of control, Fig. 5 A), and weaker inhibition at 100 µM cis Ca2+, with I' falling only to control levels (Fig. 5 B).

Minimal peptide A-induced activation in FKBP12-stripped RyRs

In contrast to strong activation of native FKBP12+ channels by peptide A1 (Figs. 3 and 4), activity of FKBP12-stripped RyRs at -40 mV was only slightly greater than normal after exposure to 0.65 µM or 32.5 µM peptide A1 with 100 nM cis Ca2+ (Fig. 6 A), and did not increase after peptide addition with 10 µM cis Ca2+, at either -40 mV or +40 mV (Fig. 6 B).



View larger version (34K):
[in this window]
[in a new window]
 
FIGURE 6   FKBP12-stripped RyRs are not significantly activated by peptide A1. (A) Records from a bilayer with 100 nM cis Ca2+. (B) records from a second bilayer with 10 µM cis Ca2+. The cis solution also contained 2 mM Na2ATP and 2 mM MgCl2. The first records in each panel were obtained under control conditions. The second and third records show activity after 10 s exposure to 6.5 µM or 32.5 µM A1, respectively. The final records were obtained ~4 min after removing A1 by perfusion with cis solution plus 2 mM Na2ATP and 2 mM MgCl2. Two RyR channels were present in each bilayer. The continuous line shows the zero current level. The broken lines indicate the maximum open conductance of one (first line) or two (second line) channels.

The control activity of the FKBP12-stripped channels (Fig. 6, A and B) was greater than that of native FKBP12+ channels (e.g., Fig. 3 above) as expected (Ahern et al., 1994). More than one channel was active in most bilayers containing FKBP12-stripped RyRs (Fig. 6, A and B) and long openings to low submaximal conductance levels were apparent, particularly at -40 mV (Fig. 6 A). I' (the mean current through the bilayer divided by the number of channels in the bilayer) during control activity at each cis [Ca2+] was greater in FKBP12-stripped RyRs than in FKBP12+ RyRs (Table 4).


                              
View this table:
[in this window]
[in a new window]
 
TABLE 4   Average control mean current (I') through FKBP12+ (native or incubated) or FKBP12-stripped RyRs at each of the three cis Ca2+ concentrations listed

An increase in activity at -40 mV was seen in 7 of 10 FKBP12-stripped RyRs with 65 nM to 32.5 µM A1 with 100 nM cis Ca2+, but was seen in only 3 of the 10 RyRs at +40 mV. On average, I' at -40 mV (100 nM cis Ca2+) showed a significant 21% increase after addition of 65 nM to 32.5 µM A1 (Fig. 7 A), compared with the 600% increase seen in native FKBP12+ RyRs.



View larger version (19K):
[in this window]
[in a new window]
 
FIGURE 7   Average effects of peptide A1 on the mean current flowing through FKBP12-stripped RyRs and FKBP12+ incubated RyRs at +40 mV and -40 mV. Relative mean current (I'p/I'c, where I'p is I' in the presence of peptide and I'c is I' under control conditions) is plotted against the logarithm of [peptide A1] in nM. Symbols show average I'p/I'c and vertical bars show ±1 SEM where this exceeds the dimensions of the symbol. Results with FKBP12-stripped RyRs were obtained with 2 mM Na2ATP and 2 mM MgCl2, and (A) 100 nM cis Ca2+ (n = 10); (B) 10 µM cis Ca2+ (n = 8); (C) 100 µM cis Ca2+ (n = 4). (D) Data for FKBP12+ incubated RyRs were obtained with 100 nM cis Ca2+, 2 mM Na2ATP, and 2 mM MgCl2 (n = 3).

Activity fell in all bilayers when >= 65 nM A1 was added with 10 µM cis Ca2+ (n = 7) or 100 µM cis Ca2+ (n = 3) and average normalized I' was less than control at both +40 mV and at -40 mV (Fig. 7, B and C). The fall in I' at -40 mV and +40 mV was significant when 32.5 µM A1 was added with 10 µM cis Ca2+ and when [A1] was >= 0.65 µM with 100 µM cis Ca2+. In contrast to FKBP12-stripped channels, FKBP12+-incubated RyRs were strongly activated by A1 at +40 mV and -40 mV, with 100 nM cis Ca2+ (Fig. 7 D). Therefore, the loss of activation in FKBP12-stripped channels was not due to the incubation procedure. Inhibition without activation was seen in another seven FKBP12-stripped RyRs when 65 nM to 32.5 µM A1 was added with 100 µM cis Ca2+, 2 mM Na2ATP, and 4 mM MgCl2. The results confirm the Ca2+ release studies and show that activation of native RyRs by peptide A1 depends on the presence of the FK506-binding protein.

Peptide A block of FKBP+ and FKBP-stripped RyRs

Effects of ATP and Mg2+

The block of RyRs by peptide A was unexpected because >= 6.5 µM of the peptide caused significant ruthenium red-sensitive Ca2+ release from TC vesicles. The recording conditions were varied to ascertain whether, in addition to depending on cis [Ca2+], channel block by peptide A was influenced by cytoplasmic (cis) ATP or Mg2+. Block was seen with 100 µM cis Ca2+ in the absence of ATP or Mg2+ (n = 11) or with 2 mM ATP (without Mg2+, n = 6). Thus channel block appeared to be independent of ATP or Mg2+ in the cis solution.

Effect of permeant ions on the inhibition of RyRs by peptide A1

Inhibition of RyR activity by peptide A was stronger at +40 mV than at -40 mV (Figs. 3 and 4). This apparent membrane potential-dependence might have been due to an effect of membrane potential per se on peptide binding and channel block, or it could be due to permeant cations entering the pore from the opposite side of the channel (i.e., the trans bath). The latter possibility would suggest a blocking mechanism in which the peptide binds within the channel pore and is displaced by ion flow from the trans chamber. To explore this possibility, we measured the effect of varying the concentration of permeant ions in the trans chamber (at constant membrane potential) on the inhibition of native FKBP12+ RyR channels by cis peptide. In these experiments the bilayers were composed of only neutral lipids (see Methods) to minimize bilayer surface potentials and possible effects of the trans solution ionic strength on surface potential and peptide binding. If charged lipids were used, changes in the ionic composition of the trans bath could alter peptide binding even if the binding site was not in the pore. The trans concentration of the permeant cation, Cs+, but not the impermeant cation, choline+, had a major effect on the strength of peptide inhibition (Fig. 8).



View larger version (30K):
[in this window]
[in a new window]
 
FIGURE 8   Inhibition of RyR activity at 0 mV by peptide A1 in the cis solution is relieved by increasing the permeant ion concentration in the trans solution. Bilayers contained 80% phosphatidylethanolamine and 20% phosphatidylcholine. The cis solution contained (in mM): 230 CsMS, 20 CsCl, 0.1 CaCl2, 2 Na2ATP, and 2 MgCl2. (A, Traces 1-3) Channel activity with 50 mM trans Cs+ (30 mM CsMS + 20 mM CsCl) so that Cs+ flowed from the cis to trans bath. Addition of 8 µM A1 almost abolished RyR activity. Traces 4 and 5 were from the same channel at 0 mV after perfusion with A1-free solution and increasing trans [Cs+] to 1000 mM by trans addition of 4 M CsMS, so that Cs+ flow was trans to cis. Under these conditions, 32 µM A1 produced relatively little inhibition. (B) In separate experiments, 1000 mM choline+, (an RyR impermeant cation) was added to the trans solution initially containing 50 mM Cs+. Adding choline+ diluted the trans [Cs+] to 30 mM, reducing RyR conductance and current amplitude. In contrast to 1000 mM trans Cs+, the 1000 mM trans choline+ did not reduce peptide A1 block of RyRs.

RyR activity at 0 mV was not altered by 4 µM cis A1, but was strongly inhibited by 8 µM A1 (Fig. 8 A, trace 3). Channel activity recovered when the bilayer was perfused with solution lacking the peptide and the current direction reversed when the Cs+ concentration in the trans chamber was increased from 50 mM to ~1000 mM (at 0 mV, Fig. 8 A, trace 4). The channel became relatively insensitive to A1 block and remained active with 32 µM A1 (Fig. 8 A, trace 5). A similar reduction in peptide block after increasing trans Cs+ to 1000 mM was seen in four of four experiments. In contrast, in two experiments where 1000 mM choline+ was added to the trans solution (to give a similar increase in ionic strength to 1000 mM Cs+), 8 µM A1 blocked the RyR in the usual way (Fig. 8 B, trace 7). The effect of the cation composition of the trans solution on the half-inhibiting concentrations of A1 are summarized in Table 5.


                              
View this table:
[in this window]
[in a new window]
 
TABLE 5   The effect of the permeant ion concentration in the trans chamber on the ability of peptide A to block RyR channels from the cis side

Increasing the concentration of the permeant cation (Cs+) in the trans solution from 50 mM to 1000 mM caused a sixfold increase in the concentration of A1 required for 50% block of the RyR. In contrast, there was a 40% reduction in the [A1] required for half-maximum block in the presence of 1000 mM choline+ (see also Fig. 8), possibly because the trans Cs+ concentration was reduced to 30 mM.

Channel openings to submaximal conductances are resistant to inhibition by peptides A1 and A2

FKBP12+ channels

The reduced channel activity (and I') produced by adding >4 µM A1 was due to fewer channel openings (Table 2), to a reduction in the number of openings to the maximum conductance in native FKBP12+ (Fig. 3; Figs. 8 and 9), and in FKBP12+-incubated channels. The native FKBP12+ RyR in Fig. 9 showed long openings (lasting for >20 ms) to the maximum conductance and to several submaximal conductance levels under control conditions at +40 mV (Fig. 9 A). When 6.5 µM peptide was added, there were only occasional brief openings to the high conductance levels, although long openings to submaximal conductance levels remained and were longer than those in the control record (Fig. 9 B). Channel openings to the maximum conductance recovered when the peptide was perfused out of the cis chamber (Fig. 9 C). The maximum conductance and three of the submaximal levels (at ~11, 33, and 67% of the maximum conductance) that could be seen under all conditions are shown by the broken lines on the records and by the arrows on the histograms. Similar effects of peptide block on openings to the maximum conductance were seen at all cis [Ca2+] tested, and were seen to a lesser extent at -40 mV.



View larger version (31K):
[in this window]
[in a new window]
 
FIGURE 9   Effects of block by peptide A1 on conductance levels in single native FKBP12+ (A-C) and FKBP12-stripped (D-F) channels at +40 mV, in the presence of 10 µM cis Ca2+. The upper records (A and D) show control activity, the middle records (B and E) were obtained after adding 6.5 µM A1 to the cis solution, and the lower records (C and F) show recovery of high conductance activity after A1 perfusion out of the cis chamber. The continuous lines show the zero current for each channel. All-points histograms, showing the probability of activity to current levels (in pA), are shown beside each record. The arrows on the histograms point to current levels [identified by I in the records (broken lines) and as peaks or discontinuities in the histograms (arrows)], that are common to all conditions. These are the maximum conductance and three submaximal conductance levels for the FKBP12+ channel and the FKBP12-stripped channel.

FKBP12-stripped channels

The effect of peptide A in preferentially blocking channel openings to maximum conductance levels was also apparent in FKBP12-stripped channels that demonstrated considerable submaximal conductance activity in the absence of peptide. As previously reported for FKBP12-stripped channels (Ahern et al., 1994, 1997a), three major submaximal conductance levels were apparent in the FKBP12-stripped channels. In the channel shown in Fig. 9, D-F, these levels were at ~17, 33, and 67% of the maximum conductance. Only very brief openings (<1 ms) to the maximum conductance were seen under control conditions, although long openings to the 67% level were apparent. Fewer, briefer openings to the 67% level were observed with 6.5 µM peptide, although long openings to the 17 and 33% levels remained (Fig. 9 E). Openings to the 67 and 100% levels recovered when the peptide was perfused out of the cis chamber (Fig. 8 F). Similar conductance levels and peptide-induced block of openings to the maximum conductance were seen in FKBP12-stripped channels at -40 mV, and with 100 nM and 100 µM cis Ca2+.

Incidental observations: RyR activation by ATP and inhibition by Mg2+

Addition of 2 mM ATP induced the expected increase in average I' through native FKBP12+ channels at both +40 mV and -40 mV with 100 µM cis Ca2+ (n = 20, Fig. 10). Addition of 4 mM MgCl2 (2.1 mM free Mg2+) then reduced I' at positive and negative potentials, but to levels that remained higher than those before addition of ATP. The response to both ATP and 4 mM MgCl2 was similar in the 20 normal and 16 FKBP12-stripped channels, although channel activity fell to levels that were not significantly different from control when 4 mM MgCl2 was added to the FKBP12-stripped channels at +40 mV (Fig. 10 B). If 2 mM MgCl2 was added simultaneously with 2 mM Na2ATP (with 0.6 mM free Mg2+), channel activity remained at levels that were not significantly different from control or greater than control (Table 6).



View larger version (22K):
[in this window]
[in a new window]
 
FIGURE 10   Histograms compare the effects of Na2ATP and MgCl2 on the mean current through native FKBP12+ and FKBP12-stripped channels. Control channel activity was recorded in the presence of 10-4 M Ca2+ (black bars). Activity after adding 2 mM ATP is shown in the gray bars and activity with 2 mM Na2ATP plus 4 mM MgCl2 is shown in the cross-hatched bars. Data are given as mean ± SE. The asterisks (**) indicate that the mean value is significantly different from that for the preceding condition, p < 0.01. The cross-hatch symbols (##) indicate that mean current with 2 mM Na2ATP plus 4 mM MgCl2 is significantly different from the that under control conditions, p < 0.01.


                              
View this table:
[in this window]
[in a new window]
 
TABLE 6   Average control mean current (I') through FKBP12+ (native) or FKBP12-stripped RyRs at each of the three cis Ca2+ concentrations listed

Since 2 mM ATP alone activated the channels (Fig. 10), channel activity with 2 mM Na2ATP plus 2 mM MgCl2 must have been depressed from the ATP-activated level. The reduction in activity with 0.6 mM free [Mg2+] does not appear to be significantly less than the block with 2.1 mM Mg2+, and the block with either Mg2+ concentration is considerably less in the presence of ATP than it is when ATP is absent (Laver et al., 1997a), confirming previous observations in cardiac RyRs (Xu et al., 1996). No consistent differences were noted between 1) the native FKBP12+ and FKBP12-stripped channels, or 2) between the effects of ATP and Mg2+ at different cis Ca2+ concentrations.

    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES

We show here that peptide A (corresponding to the N terminal of the DHPR II-III loop), at concentrations from 65 nM to 32.5 µM, activates native RyR channels at -40 mV with cis [Ca2+]s of 100 nM, 10 µM, and 100 µM. The peptide also inhibited channel activity in native RyRs and, at >4 µM, reduced the mean current at +40 mV to less than control levels when cis [Ca2+] was 100 µM. Activation by peptide A was expected because it has been shown that the peptide increases [3H]ryanodine binding to, and releases Ca2+ from, SR vesicles (El-Hayek et al., 1995). The blocking action of the peptide was not expected from previous single channel studies on longer segments of the II-III loop (Lu et al., 1995), although a decline in the rate of peptide-activated Ca2+ release from SR is apparent with higher concentrations of a fragment of the peptide (El-Hayek and Ikemoto, 1998).

Peptide A activation of the skeletal RyR

Peptide A activation overcame Mg2+ block of RyR activity. Mg2+ block reduced RyR activity and suppressed Ca2+ release through the channel in resting muscle (Lamb and Stephenson, 1991). Peptide A activated RyRs in the presence of ~0.6 mM free Mg2+ in Ca2+ release experiments, or 0.6 mM to 2.1 mM free Mg2+ in single channel experiments (with 10-7 to 10-4 M Ca2+). Thus, peptide A-induced activation mimics ECC insofar as it can overcome Mg2+-inhibition of RyR activity.

The degree of activation of the RyR by peptide A was not as large as expected for the primary trigger of RyR opening during ECC. Channel open probability (Po) with 0.65-6.5 µM peptide remained well below 1.0 (Table 1), while the rate of Ca2+ release from TC in our experiments, and in the faster release in stop-flow experiments (El-Hayek and Ikemoto, 1998), remain slower than Ca2+ release during ECC (Melzer et al., 1987). The lower-than-expected activation could indicate that a conformational change in the II-III loop occurs during ECC, but does not occur when the peptide is isolated from the remainder of the DHPR and is not under the influence of the T-tubule membrane potential. Alternatively (or in addition), the relatively small increase in I' and Po could be due to the strong concurrent inhibition. Although inhibition per se was not apparent in SR Ca2+ release, inhibition could have reduced the degree of activation (as indicated by the increased activity after removal of peptide A from the cis chamber).

It is likely that peptide A activation of the RyR depends on the highly positively charged residues in the C half of the peptide. A smaller II-III loop peptide containing these arginine and lysine residues (Arg Lys Arg Arg Lys Met Ser Arg Gly Leu), increases 3H-ryanodine binding and releases Ca2+ from SR (El-Hayek and Ikemoto, 1998; Dulhunty et al., 1999). Thus it is likely that it is this segment of the II-III loop that binds to skeletal RyRs at residues 1076-1112 (Leong and Maclennan, 1998). Skeletal type ECC also requires region D3, residues 1872-1923 (Nakai et al., 1998a), and perhaps region D2 (1342-1403, Yamazawa et al., 1997) of the RyR. The involvement of these diverse regions of the RyR indicates a complex transduction pathway through the channel protein between its interaction with the DHPR and the ion channel pore. This is not surprising, given the size and complex structure of the protein (Radermacher et al., 1994; Orlova et al., 1996; Wagenknecht and Radermacher, 1997; Wagenknecht et al., 1997).

Importance of Ser687 in II-III loop activation of RyRs

In our studies, enhanced peptide-induced Ca2+ release from TC and activation of single RyRs at lower peptide concentrations were seen with the Ser687 Ala substitution. This is in contrast to the abolition of activation seen with the same substitution in the full II-III loop (Lu et al., 1995). However, Ser687 Ala substitution in the entire DHPR alpha 1 subunit does not alter the ability of the DHPR to support skeletal-type ECC (Nakai et al., 1998b). The reasons for these conflicting results are not clear. However, the Ser687 Ala substitution could well produce a structural change that prevents the full II-III loop from activating the RyR, but that enhances activation by the shorter peptides. Enhanced activation may not have been detected within the resolution of the ECC studies (Nakai et al., 1998b).

The FK506 binding protein

The ability of peptide A to activate RyRs was substantially reduced in FKBP12-stripped RyRs. The removal of FKBP12 reduces the number of RyR openings to the maximum conductance, but does not alter the regulation of the channel by Ca2+ (Ahern et al., 1997b), ATP, Mg2+, or caffeine (see Results). The influence of FKBP12 on channel activation by A1 is unique among these ligands, which supports suggestions that FKBP12 plays a role in RyR activation during ECC (Ahern et al., 1994, 1997a; Brillantes et al., 1994; Mayrleitner et al., 1994; Lamb and Stephenson, 1996).

The putative FKBP12 binding domain at 2407-2520 (Cameron et al., 1997) is located on the surface of the RyR that opposes the T-tubule membrane (Wagenknecht et al., 1997). Four FKBP12 molecules bind to each RyR, i.e., one per subunit (Jayaraman et al., 1992; Timerman et al., 1993; Wagenknecht et al., 1996, 1997). The II-III loop binding domain must be located on the same surface of the RyR to enable the DHPR to bind to the RyR. Since skeletal muscle DHPRs are clumped into tetrads, which oppose every second RyR (Block et al., 1988), each subunit of every second RyR is likely to interact with the II-III loop of one of the DHPRs in a tetrad. The T-tubule opposing surface of each subunit of the RyR must contain an FKBP12 binding site and a II-III loop binding site. An interaction between FKBP12 binding and activation of RyRs by the II-III loop has been suggested by the fact that FK506 can disrupt depolarization-induced Ca2+ release from the SR (Lamb and Stephenson, 1996).

Physiological interactions between the DHPR and the RyR during ECC

It is not known whether the II-III loop is bound to the RyR in vivo or binding occurs only during ECC. In the latter case, binding alone could be sufficient to activate the RyR although, as mentioned previously, the activation produced by peptide binding is not as strong as might be expected. However, there is evidence that a complex can be formed between the RyR and DHPR (Marty et al., 1994; Murray and Ohlendieck, 1998). If there is a stable II-III loop-RyR complex, then RyR activation during ECC could depend on a conformational change in the II-III loop being transmitted, through the DHPR/RyR interaction site, to the RyR.

Although studies with synthetic peptides and RyRs in bilayers or vesicles clearly show that peptide A can activate the calcium release channel, apparently conflicting results have been obtained from ECC studies with dysgenic myotubes expressing chimeric DHPRs. It is clear that the skeletal ECC (independent of external Ca2+) requires the skeletal II-III loop and will not proceed if the loop contains the cardiac sequence (Tanabe et al., 1990). However, when chimeras are constructed with parts of the II-III loop, skeletal-type ECC proceeds when the A portion contains either the cardiac or skeletal sequence (Nakai et al., 1998b). Skeletal ECC has an absolute requirement for the skeletal sequence in residues 725-742 (encompassed in the C portion of the II-III loop according to El-Hayek et al., 1995). Lu et al. (1994, 1995) found that both the cardiac and skeletal II-III loops increased ryanodine binding to SR vesicles and activated RyR channels, suggesting that both the cardiac and skeletal II-III loops bind to the skeletal RyR, and in agreement with the ECC studies. The II-III loops presumably bind to the RyR at the A region, which contains several arginine and lysine residues in both the skeletal and cardiac isoforms.

One hypothesis that could explain most observations is that the positively charged A region of the II-III loop binds to the RyR, causing an increase in RyR activity. Full activation of the RyR requires a conformational change at the binding site, which is initiated by the voltage sensor in the S4 segment of the DHPR and is transmitted through the C region (725-742) of the II-III loop. Either the skeletal or cardiac sequence of the II-III loop binds to (or interacts with) the skeletal RyR. However, skeletal-type ECC requires transmission of T-tubule depolarization to the II-III loop/RyR interaction site, and this can only proceed if residues 725-742 contain the skeletal DHPR sequence.

Peptide A inhibition of the skeletal RyR

The peptide inhibition site is distinct from the II-III loop activation site because 1) inhibition is greatest at 100 µM cis Ca2+, while activation is greatest at 100 nM cis Ca2+; 2) inhibition, but not activation, depends on the direction of current flow; and 3) unlike activation, inhibition is not disrupted by removing FKBP12. The fact that inhibition by cis peptide A was reduced when Cs+ flows from trans to cis is consistent with the peptides blocking by binding to the pore or vestibule of the RyR, since Cs+ could enter the pore from the trans bath and compete with the peptide for its binding site. This hypothesis is supported by the fact that high trans [choline+], which does not pass through RyR channels, did not affect cis peptide inhibition. The sensitivity of peptide block to the flow of permeant cations may also account for its voltage-dependence, since at negative potentials the electric field in the pore will favor cation permeation from the trans side, whereas positive potentials will oppose it.

In contrast to peptide A, the full-length DHPR II-III loop has not been reported to inhibit RyR activity (Lu et al., 1994, 1995). Failure of the full-length II-III loop to block can be explained if the blocking site is in the channel pore, since the bulk of the longer peptide could restrict its access to the blocking site. The observation is consistent with the hypothesis that there are separate inhibition and activation sites.

Permeant ions flowing from the opposite side of a channel have been shown elsewhere to reduce the binding of pore blocking peptides [e.g., charybdotoxin block of the Ca2+-activated K+ channel (MacKinnon and Miller, 1988)]. A toxin that blocks the K+ channel pore also blocks RyRs, possibly because positively charged arginine and lysine residues in the peptides bind to negative charges near the channel pore (Mead et al., 1998). Peptide A, also rich in arginine and lysine residues, may bind to the RyR at a site similar to the toxin binding site.

Two factors that need to be considered in developing a model for peptide binding in the channel pore are 1) inhibition depends on cis [Ca2+] and is greatest at 100 µM cis Ca2+; and 2) inhibition preferentially targeted maximal conductance openings, while leaving openings to submaximal conductances intact. The blocking mechanism must differ from ryanodine block, which causes equal depression of all conductance levels (Ahern et al., 1997a). The sensitivity of peptide inhibition to direction of flow of permeant ions may account for the fact that inhibition was not apparent in vesicle experiments, since Ca2+ flow from the lumen to cytoplasm (trans to cis) would reduce peptide-induced inhibition. The cis [Ca2+]-dependence of inhibition would also reduce the efficacy of inhibition in the vesicle experiments since the extravesicular [Ca2+] was considerably less than 100 µM during maximum rates of release. Although inhibition dominated the effect of peptide A on RyRs in bilayers, it might not reflect a physiological action of the DHPR, since the II-III loop in vivo is physically constrained by the DHPR's location in the T-tubule membrane and may not be free to enter the channel pore. However, inhibition must be considered when studying the action of the II-III loop, or loop peptides, on Ca2+ release from SR or on single RyR channels.

In conclusion, we have shown that peptides corresponding to an amino acid sequence in the N-terminal region of the II-III loop of the skeletal muscle DHPR activate ryanodine-sensitive Ca2+ release from SR vesicles and activate single RyR channels incorporated into lipid bilayers. Study of RyR channel activation by the peptide is complicated by a competing strong inhibitory action of the peptide. The results show that activation of RyRs by the peptide is not dependent on Ser687 in the DHPR II-III loop and that activation of the RyR by the peptide is facilitated when FKBP12 is bound to the RyR. These observations suggest that activation of the RyR by the DHPR II-III loop requires a complex sequence of signals passing from the II-III loop binding site to the RyR channel pore. The inhibitory action of peptide binding could provide a useful tool to probe the RyR pore, but inhibition is unlikely to be relevant to RyR function in vivo.

    ACKNOWLEDGMENTS

The authors are grateful to Joan Stivala, Glen Whalley, and Bernie Keys for their assistance.

Professor Gallant was supported by grants from the National Institutes of Health and National Science Foundation. Dr. D. R. Laver was supported by a grant from the Australian National Health and Medical Research Council.

    FOOTNOTES

Received for publication 22 July 1998 and in final form 5 April 1999.

Address reprint requests to Dr. A. F. Dulhunty, John Curtin School of Medical Research, Australian National University, P.O. Box 334, Canberra, ACT 2601, Australia. Tel.: 61 6 249 4491; Fax: 61 6 249 4761; E-mail: angela.dulhunty{at}anu.edu.au.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
METHODS